FTY720: Targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity

Current Opinion in Immunology

Volumn 14, Issue 5, 2002, Pages 569-575

  Brinkmann, Volker ^a   Lynch, Kevin R ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; MIZORIBINE; PERTUSSIS TOXIN; PREDNISOLONE; SPHINGOSINE 1 PHOSPHATE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EXPERIMENTAL MODEL; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPH NODE; LYMPHOCYTE; LYMPHOID TISSUE; MULTIPLE SCLEROSIS; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS ISLET TRANSPLANTATION; PEYER PATCH; PHOSPHORYLATION; RECEPTOR UPREGULATION; REVIEW; T LYMPHOCYTE; TRANSPLANTATION; VIRUS INFECTION;

EID: 0036773971     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(02)00374-6     Document Type: Review

References (44)

1. Brinkmann V., Pinschewer D.D., Feng L., Chen S. FTY720: Altered lymphocyte traffic results in allograft protection. Transplantation. 72:2001;764-769. Review on the activity of FTY720 in experimental models of transplantation and autoimmunity.
2. Chiba K., Yanagawa Y., Masubuchi Y., Kataoka H., Kawaguchi T., Ohtsuki M., Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 160:1998;5037-5044. First demonstration that FTY720 sequesters lymphocytes from blood and spleen into LN and PP.
3. Pinschewer D.D., Ochsenbein A.F., Odermatt B., Brinkmann V., Hengartner H., Zinkernagel R.M. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion, and memory. J Immunol. 164:2000;5761-5770. Demonstration that FTY720 does not impair T cell activation, expansion and memory in response to systemic infection, and that the drug does not delay viral clearance. First demonstration that FTY720 has potential to inhibit autoimmunity against islet cells.
4. Brinkmann V., Chen S., Feng L., Pinschewer D., Nikolova Z., Hof R. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc. 33:2001;530-531.
5. Fujita T., Inoue K., Yamamoto S., Ikumoto T., Sasaki S., Toyama R., Chiba K., Hoshino Y., Okumoto T. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot. 47:1994;208-215.
6. Kiuchi M., Adachi K., Kohara T., Teshima K., Masubuchi Y., Mishina T., Fujita T. Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720. Bioorg Med Chem Lett. 8:1998;101-106.
7. Kiuchi M., Adachi K., Kohara T., Minoguchi M., Hanano T., Aoki Y., Mishina T., Arita M., Nakao N., Ohtsuki M., et al. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. J Med Chem. 43:2000;2946-2961.
8. Chen J.K., Lane W.S., Schreiber S. The identification of myriocin-binding proteins. Chem Biol. 6:1999;221-235.
9. Hla T., Lee M.J., Ancellin N., Paik J.H., Kluk M.J. Lysophospholipids - receptor revelations. Science. 294:2001;1875-1878. Review on the S1P receptor biology with emphasis on their potential as therapeutic targets.
10. Lynch K.R., Im D.S. Life on the edge. Trends Pharmacol Sci. 20:1999;473-475.
11. Pyne S., Pyne N. Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol Ther. 88:2000;115-131. Comprehensive summary on S1P biology, including sphingolipid metabolism, receptor-mediated versus intracellular actions of S1P, S1P receptors and therapeutic potential.
12. Goetzl E.J., An S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J. 12:1998;1589-1598.
13. English D., Welch Z., Kovala A.T., Harvey K., Volpert O.V., Brindley D.N., Garcia J.G. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J. 14:2000;2255-2265.
14. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I., Ui M., Okajima F. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem. 276:2001;31780-31785.
15. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., Bruns C., Prieschl E., Baumruker T., Hiestand P., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 277:2002;21453-21457. Demonstration that FTY720 is a substrate of SK1a, and is phosphorylated by lymphoid tissue explants, and that the phosphorylated form is a potent agonist at four S1P receptors. The agonistic signal alters the intrinsic mobility of cells and alters lymphocyte traffic, but does not lead to apoptosis. First evidence that FTY720 is highly effective in models of human multiple sclerosis.
16. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., Thornton R., Shei G.J., Card D., Keohane C., et al. Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science. 296:2002;346-349. Demonstration that FTY720 is phosphorylated in vivo and that S1P receptor agonists including FTY720-P empty lymphoid sinuses by retention of lymphocytes on the abluminal side of the SLE, thereby inhibiting egress to lymph.
17. Nikolova Z., Hof A., Rudin M., Baumlin Y., Kraus G., Hof R.P. Prevention of graft vessel disease by combined FTY720 and Cyclosporin A treatment in the DA to Lewis rat carotid artery transplantation model. Transplantation. 69:2000;2525-2530.
18. Háyry P. Chronic rejection: risk factors, regulation, and possible sites of therapeutic intervention. Transplant Proc. 30:1998;2407-2415.
19. Korbutt G.S., Warlock G.L., Rajotte R.V. Islet transplantation. Adv Exp Med Biol. 426:1997;397-406.
20. Yamasaki T., Inoue K., Hayashi H., Gu Y., Setoyama H., Ida J., Cui W., Kawakami Y., Kogire M., Imamura M. Effect of a new immunosuppressive agent, FTY720, on survival of islet allografts. Cell Transplant. 7:1998;403-406.
21. Fu F., Hu S., Deleo J., Li S., Hopf C., Hoover J., Wang S., Brinkmann V., Lake P., Shi V. Longterm islet graft survival in STZ and autoimmune induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation. 73:2002;1425-1430.
22. Matsuura M., Imayoshi T., Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol. 22:2000;323-331.
23. Kitabayashi H., Isobe M., Watanabe N., Suzuki J., Yazaki Y., Sekiguchi M. FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J Cardiovasc Pharmacol. 35:2000;410-416.
24. Kurose S., Ikeda E., Tokiwa M., Hikita N., Mochizuki M. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res. 70:2000;7-10.
25. Okazaki H., Hirata D., Kamimura T., Sato H., Iwamoto M., Yoshio T., Masuyama J., Fujimura A., Kobayashi E., Kano S., et al. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol. 29:2002;707-716.
26. Miyamoto T., Matsumori A., Hwang M.W., Nishio R., Ito H., Sasayama S. Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J Am Coll Cardiol. 37:2001;1713-1718.
27. Yanagawa Y., Sugahara K., Kataoka H., Kawaguchi T., Masubuchi Y., Chiba K. FTY720, a novel immunosuppressant possessing unique mechanisms. II. FTY720 prolongs skin allograft survival by decreasing T-cell infiltration into grafts but not cytokine production in vivo. J Immunol. 160:1998;5493-5499. Demonstration that the protective effect of FTY720 after transplantation of allogeneic skin correlates with a reduced infiltration of T cells into the transplant.
28. Hwang M.W., Matsumori A., Furukawa Y., Ono K., Okada M., Iwasaki A., Hara M., Sasayama S. FTY720, a new immunosuppressant, promotes long term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation. 100:1999;1322-1329.
29. Chiba K., Hoshino Y., Suzuki C., Masubuchi Y., Yanagawa Y., Ohtsuki M., Sasaki S., Fujita T. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with CsA in rats. Transplant Proc. 28:1996;1056-1059.
30. Bai Y., Liu J., Wang Y., Honig S., Qin L., Boros P., Bromberg J.S. L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J Immunol. 168:2002;1579-1589.
31. Brinkmann V., Pinschewer D., Chiba K., Feng L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci. 21:2000;49-52.
32. Chen S., Bacon K.B., Garcia G., Liao R., Pan Z.K., Sullivan S.K., Nakano H., Matsuzawa A., Brinkmann V., Feng L. FTY720, a novel transplantation drug, modulates lymphocyte migratory responses to chemokines. Transplant Proc. 33:2001;3057-3063. First demonstration that FTY720 increases the intrinsic mobility of lymphocytes and their chemotactic response.
33. Kunkel E.J., Butcher E.C. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 16:2002;1-4.
34. Henning G., Ohl L., Junt T., Reiterer P., Brinkmann V., Nakano H., Hohenberger W., Lipp M., Forster R. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med. 194:2001;1875-1881. Demonstration that FTY720 is active in CCR7-deficient mice and plt mice, suggesting that the FTY720-induced lymphocyte homing is independent of CCR7 and its chemokine ligands.
35. Yagi H., Kamba R., Chiba K., Soga H., Yaguchi K., Nakamura M., Itoh T. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol. 30:2000;1435-1444.
36. Lee M.J., Thangada S., Claffey K.P., Ancellin N., Liu C.H., Kluk M., Volpi M., Sha'afi R.I., Hla T. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 99:1999;301-312.
37. Beer M.S., Stanton J.A., Salim K., Rigby M., Heavens R.P., Smith D., McAllister G. EDG receptors as a therapeutic target in the nervous system. Ann NY Acad Sci. 905:2000;118-131.
38. Nagahara Y., Ikekita M., Shinomiya T. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol. 165:2000;3250-3259.
39. Matsuda S., Minowa A., Suzuki S., Koyasu S. Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J Immunol. 162:1999;3321-3326.
40. Brinkmann V., Wilt C., Kristofic C., Nikolova Z., Hof R.P., Chen S., Albert R., Cottens S. FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant Proc. 33:2001;3078-3080.
41. Azuma H., Takahara S., Ichimaru N., Wang J.D., Itoh Y., Otsuki Y., Morimoto J., Fukui R., Hoshiga M., Ishihara T., et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 62:2002;1410-1419.
42. Liliom K., Sun G., Bunemann M., Virag T., Nusser N., Baker D.L., Wang D.A., Fabian M.J., Brandts B., Bender K., et al. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J. 355:2001;189-197.
43. Guo J., MacDonell K.L., Giles W.R. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch. 438:1999;642-648.
44. Mazurais D., Robert P., Gout B., Berrebi-Bertrand I., Laville M.P., Calmels T. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem. 50:2002;661-670.